Skip to content

Takeda Pharmaceutical

US · TAK #400 by market cap Listed 1970
21.77 +0.36 +1.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.19 Expensive vs history 95th percentile
5-year average 0.99 · #30 of 70 in Drug Manufacturers - Specialty & Generic
P/E ratio 306.14 Expensive vs history 100th percentile
5-year average 40.04 · forward 39.28 · #25 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 2.34 Expensive vs history 100th percentile
5-year average 1.65 · forward 2.30 · #41 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%
Viatris (VTRS) 22.50B -37.04 1.64 2.45%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value21.02 Economic moatNone UncertaintyLow

Trading 3.5% above Morningstar's fair value estimate.

Fair value

Takeda Pharmaceutical Co Ltd receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $21.02 per share, which has a low uncertainty rating.

The company's lack of growth weakens our estimated valuation. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 4.6%, which ranks in the bottom 45% compared with global peers. Unfavorable revenue growth over the last three years could be considered concerning when it comes to the future revenue and cash flow potential of the business. We believe this is a sign that shares could be expensive.

Alternatively, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 70.8%, a core component of valuation, falls in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Takeda Pharmaceutical discussion 0 comments

Add a comment